RASRx, a US-based startup dedicated to developing therapies for rare diseases, received equity funding from CureDuchenne Ventures LLC, a venture philanthropy company that funds research to find a cure for Duchenne muscular dystrophy*.
The amount of the investment was not disclosed. In conjunction with the funding, Jak Knowles, Managing Director of CureDuchenne Ventures, will join RASRx’ Board of Directors.
The company intends to use the funds to initiate and accelerate critical preclinical development studies and manufacturing.
Led by Kathleen Rodgers, RASRx is developing an oral therapy that has shown positive effects on muscle function in a mdx mouse model of Duchenne, demonstrating improved muscle strength and regeneration, with decreased muscle inflammation and fibrosis.
Formed by CureDuchenne, a national nonprofit that has a track record of supporting research and raising awareness of the disease.
CureDuchenne Ventures LLC collaborates with pharmaceutical and biotechnology companies to facilitate the development of drugs to treat Duchenne muscular dystrophy.